Shilpa Medicare on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its facility in Raichur, Karnataka. An EIR is given to a unit on successful closure of an inspection conducted by the United States Food and Drug Administration (USFDA). The company announced successful closure of the inspection conducted at its active pharmaceutical ingredient (API) manufacturing site at Raichur with the receipt of EIR from the USFDA, Shilpa Medicare said in a filing to the BSE. The inspection was conducted from July 22-26, it added. The stock of Shilpa Medicare closed 2.86 per cent higher at ₹298.30 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.